GALT GALECTIN THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, GALECTIN THERAPEUTICS INC reported revenue of n/a, net income of −$9.11M and diluted EPS of −$0.14; for the fiscal year ended December 2025 revenue was n/a.
GALT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$20.1M, net income −$30.8M (margin n/a), EPS −$0.48
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$42.4M, net income −$47.0M (margin n/a), EPS −$0.76
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$38.1M, net income −$41.1M (margin n/a), EPS −$0.74
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$38.4M, net income −$38.8M (margin n/a), EPS −$0.65
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$30.2M, net income −$30.5M (margin n/a), EPS −$0.52
GALT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$9.11M, EPS −$0.14
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.05M, EPS −$0.08
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.50M, EPS −$0.08
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.18M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue n/a, net income −$7.52M, EPS −$0.12
- Quarter ended Mar 31, 2025: revenue n/a, net income −$9.63M, EPS −$0.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$12.0M, EPS −$0.19
- Quarter ended Sep 30, 2024: revenue n/a, net income −$11.2M, EPS −$0.18
- Quarter ended Jun 30, 2024: revenue n/a, net income −$12.4M, EPS −$0.20
- Quarter ended Mar 31, 2024: revenue n/a, net income −$11.5M, EPS −$0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$10.00M, EPS −$0.16
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.4M, EPS −$0.24
- Quarter ended Jun 30, 2023: revenue n/a, net income −$9.11M, EPS −$0.15
- Quarter ended Mar 31, 2023: revenue n/a, net income −$11.5M, EPS −$0.19
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$10.6M, EPS −$0.18
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.60M, EPS −$0.14
- Quarter ended Jun 30, 2022: revenue n/a, net income −$9.61M, EPS −$0.16
- Quarter ended Mar 31, 2022: revenue n/a, net income −$9.93M, EPS −$0.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.22M, EPS −$0.12
- Quarter ended Sep 30, 2021: revenue n/a, net income −$8.52M, EPS −$0.14
GALT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$23.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$41.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$33.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$31.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$24.3M, share buybacks n/a
GALT balance sheet
- Jun 30, 2026: cash $13.3M, total assets $14.8M, total liabilities $152M, shareholders' equity −$139M
- Mar 31, 2026: cash $14.1M, total assets $15.8M, total liabilities $146M, shareholders' equity −$132M
- Dec 31, 2025: cash $17.7M, total assets $19.5M, total liabilities $146M, shareholders' equity −$128M
- Sep 30, 2025: cash $11.5M, total assets $12.9M, total liabilities $136M, shareholders' equity −$125M
- Jun 30, 2025: cash $13.8M, total assets $15.6M, total liabilities $133M, shareholders' equity −$119M
- Mar 31, 2025: cash $7.43M, total assets $9.53M, total liabilities $122M, shareholders' equity −$114M
- Dec 31, 2024: cash $15.1M, total assets $17.5M, total liabilities $121M, shareholders' equity −$105M
- Sep 30, 2024: cash $27.1M, total assets $29.0M, total liabilities $121M, shareholders' equity −$94.2M
Is GALT profitable?
No. GALECTIN THERAPEUTICS INC lost $27.8M over the last four quarters.
What is GALT's EPS?
Diluted earnings per share over the last four quarters were −$0.43; −$0.14 in the latest quarter.